Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction
P Calabresi, A Mechelli, G Natale… - Cell death & …, 2023 - nature.com
Although the discovery of the critical role of α-synuclein (α-syn) in the pathogenesis of
Parkinson's disease (PD) is now twenty-five years old, it still represents a milestone in PD …
Parkinson's disease (PD) is now twenty-five years old, it still represents a milestone in PD …
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …
features, with α-synuclein pathology as the gold standard to establish the definitive …
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria
GU Höglinger, CH Adler, D Berg, C Klein… - The Lancet …, 2024 - thelancet.com
With the hope that disease-modifying treatments could target the molecular basis of
Parkinson's disease, even before the onset of symptoms, we propose a biologically based …
Parkinson's disease, even before the onset of symptoms, we propose a biologically based …
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
C Gao, J Jiang, Y Tan, S Chen - Signal transduction and targeted …, 2023 - nature.com
Microglia activation is observed in various neurodegenerative diseases. Recent advances in
single-cell technologies have revealed that these reactive microglia were with high spatial …
single-cell technologies have revealed that these reactive microglia were with high spatial …
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
A Okuzumi, T Hatano, G Matsumoto, S Nojiri, S Ueno… - Nature medicine, 2023 - nature.com
Abnormal α-synuclein aggregation is a key pathological feature of a group of
neurodegenerative diseases known as synucleinopathies, which include Parkinson's …
neurodegenerative diseases known as synucleinopathies, which include Parkinson's …
Structures of α-synuclein filaments from human brains with Lewy pathology
Parkinson's disease (PD) is the most common movement disorder, with resting tremor,
rigidity, bradykinesia and postural instability being major symptoms. Neuropathologically, it …
rigidity, bradykinesia and postural instability being major symptoms. Neuropathologically, it …
Genetics and pathogenesis of Parkinson's syndrome
H Ye, LA Robak, M Yu, M Cykowski… - Annual Review of …, 2023 - annualreviews.org
Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
S Palmqvist, M Rossi, S Hall, C Quadalti… - Nature Medicine, 2023 - nature.com
Abstract α-Synuclein aggregates constitute the pathology of Lewy body (LB) disease. Little is
known about the effects of LB pathology in preclinical (presymptomatic) individuals, either as …
known about the effects of LB pathology in preclinical (presymptomatic) individuals, either as …
Clinical effects of Lewy body pathology in cognitively impaired individuals
C Quadalti, S Palmqvist, S Hall, M Rossi… - Nature Medicine, 2023 - nature.com
There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …
Parkinson disease-associated cognitive impairment
D Aarsland, L Batzu, GM Halliday… - Nature reviews Disease …, 2021 - nature.com
Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …